MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

215.01
+1.85
+0.87%
After Hours: 215.01 0 0.00% 16:54 05/07 EDT
OPEN
214.36
PREV CLOSE
213.16
HIGH
216.77
LOW
213.81
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
306.08
52 WEEK LOW
202.57
MARKET CAP
55.66B
P/E (TTM)
20.46
1D
5D
1M
3M
1Y
5Y
Cystic Fibrosis Market 2021: Latest Industry Size, Growth, Share, Demand, Trends, Competitive Landscape and Forecasts to 2023 with Top Countries Data
May 07, 2021 (AmericaNewsHour) -- The major factors responsible for the growth of global cystic fibrosis market are; development of new drugs and therapies,...
AmericaNewsHour · 7h ago
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
Zacks.com · 7h ago
Multidrug Resistant Bacteria Treatment Market 2021 Size, Share, Growth, Study, Status and Forecast To 2027| COVID 19 impact on Revenue of Top Key Players
The Express Wire · 16h ago
Orphan drugs Market Segments, Trends, Industry Growth, Landscape and Demand by Forecast to 2027
May 06, 2021 (Heraldkeepers) -- Orphan Drugs Market Research Report: Information by Drug Type (Biologics & Non-Biologics), Sale (Generics & Prescribed),...
Heraldkeepers · 1d ago
Orphan diseases Market Analysis Revealing Key Drivers, Growth Trends and Competitive Assessment through 2027
May 06, 2021 (Heraldkeepers) -- Market Scenario: Global orphan diseases market also known as rare disease is growing rapidly. It affects a very small...
Heraldkeepers · 1d ago
Hellman Jordan Management Co Inc Buys Exxon Mobil Corp, Industrial Select Sector SPDR, ...
GuruFocus News · 1d ago
Goelzer Investment Management, Inc. Buys Freeport-McMoRan Inc, NiSource Inc, Rio Tinto PLC, ...
GuruFocus News · 1d ago
Fagan Associates, Inc. Buys Ally Financial Inc, General Motors Co, Vertex Pharmaceuticals Inc, ...
GuruFocus News · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRTX. Analyze the recent business situations of Vertex Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRTX stock price target is 284.68 with a high estimate of 347.00 and a low estimate of 250.00.
EPS
Institutional Holdings
Institutions: 1.28K
Institutional Holdings: 252.30M
% Owned: 97.46%
Shares Outstanding: 258.87M
TypeInstitutionsShares
Increased
374
22.12M
New
155
2.16M
Decreased
310
23.25M
Sold Out
126
3.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Executive Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Executive Vice President/Chief Administrative Officer
Charles Milstein
Chief Financial Officer/Executive Vice President
Charles Wagner
Executive Vice President/Chief Administrative Officer
Michael Parini
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Stuart Arbuckle
Executive Vice President
Carmen Bozic
Executive Vice President
Amit Sachdev
Senior Vice President
Kimberly White
Executive Vice President
Bastiano Sanna
Executive Vice President
Ourania Tatsis
Senior Vice President/Chief Accounting Officer
Paul Silva
Director
David Greenway
Lead Director/Independent Director
Bruce Sachs
Senior Vice President
Nia Tatsis
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
Alan Garber
Independent Director
lloyd Carney
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret McGlynn
Independent Director
Diana McKenzie
Independent Director
William Young
No Data
About VRTX
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.